Publication:
Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus).

No Thumbnail Available

Date

2022-02-28

Authors

Pitarch Castellano, I
Cabrera-Serrano, M
Calvo Medina, R
Cattinari, M G
Espinosa García, S
Fernández-Ramos, J A
García Campos, O
Gómez-Andrés, D
Grimalt Calatayud, M A
Gutiérrez Martínez, A J

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by a biallelic mutation of the SMN1 gene, located on the long arm of chromosome 5, and predominantly affects the motor neurons of the anterior horn of the spinal cord, causing progressive muscle weakness and atrophy. The development of disease-modifying treatments is significantly changing the natural history of SMA, but uncertainty remains about which patients can benefit from these treatments and how that benefit should be measured. A group of experts specialised in neurology, neuropediatrics, and rehabilitation and representatives of the Spanish association of patients with SMA followed the Delphi method to reach a consensus on 5 issues related to the use of these new treatments: general aspects, treatment objectives, outcome assessment tools, requirements of the treating centres, and regulation of their use. Consensus was considered to be achieved when a response received at least 80% of votes. Treatment protocols are useful for regulating the use of high-impact medications and should guide treatment, but should be updated regularly to take into account the most recent evidence available, and their implementation should be assessed on an individual basis. Age, baseline functional status, and, in the case of children, the type of SMA and the number of copies of SMN2 are characteristics that should be considered when establishing therapeutic objectives, assessment tools, and the use of such treatments. The cost-effectiveness of these treatments in paediatric patients is mainly influenced by early treatment onset; therefore, the implementation of neonatal screening is recommended. The RET-AME consensus recommendations provide a frame of reference for the appropriate use of disease-modifying treatments in patients with SMA.

Description

MeSH Terms

Child
Consensus
Delphi Technique
Humans
Infant, Newborn
Muscular Atrophy, Spinal
Neurodegenerative Diseases
Spain

DeCS Terms

CIE Terms

Keywords

Atrofia muscular espinal (AME), Delphi, Neuromuscular, Spinal muscular atrophy (SMA), Tratamiento, Treatment

Citation